Dr. Vijay Pandey is Research Assistant Professor at the Tsinghua-Berkeley Shenzhen Institute (TBSI), China. Prior to current position, Dr. Vijay was a Research Fellow at the Cancer Science Institute of Singapore, National University of Singapore. He obtained a doctoral degree (Ph.D.) in Molecular Medicine from the University of Auckland, New Zealand. His primary research interest is directed toward understanding the basis of molecular signatures and their significance in the development of human malignancies. He has led multiple projects that have successfully designed, synthesized, and identified lead candidates for anticancer therapy. Dr. Vijay has published multiple peer-reviewed research articles as the first author in leading international journals in the field such as Breast Cancer Research, Endocrinology, Medicine, Cell Death & Disease (Nature) and PNAS (USA). Targeted therapies, which block the growth and spread of cancer cells by targeting specific molecules required for tumor development and progression, are currently one of the most exciting prospects for the treatment of cancer. Dr. Vijay’s research focuses on the discovery of novel secreted or membrane-bound (transmembrane) therapeutic targets for the treatment of human malignancies.